Background: Targeted therapies for non-small lung cancer (NSCLC) have vastly improved survival and other outcomes for patients whose tumors have genetic mutations such as ALK, BRAF, EGFR, and ROS1. Identification of genetic mutations often
Search Results
HSR19-099: Harnessing the Voice of Patients With Genetic Mutations in NSCLC Treatment
Suepattra G. May, Caroline Huber, Alison R. Silverstein, Mark Linthicum, Jason Shafrin, Katie Brown, Upal Basu Roy, and Jennifer Bright
Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer
Jaideep Sandhu, Chongkai Wang, and Marwan Fakih
, several studies have shown that HER2 amplification is implicated in the resistance to EGFR-targeted therapies. 1 , 4 , 9 , 10 Multiple studies have provided scientific evidence to support HER2-directed therapies in CRC. 3 , 8 These studies interrogated
Individualized Approach to Management of Light Chain Amyloidosis
Giovanni Palladini and Paolo Milani
, cyclophosphamide/bortezomib/dexamethasone; Dara, daratumumab; DL co , diffusing capacity of the lung for carbon monoxide; EF, ejection fraction; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; LMDex, lenalidomide/ melphalan/dexamethasone; NT
Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019
Michael P. Douglas, Stacy W. Gray, and Kathryn A. Phillips
policies that addressed single-gene ctDNA testing (eg, EGFR , ALK , BRAF ) that did not include a provision for ctDNA-based panel testing ( supplemental eAppendix 3 ). Private Payers We searched the Canary Insights Database with the terms “liquid biopsy
HSR19-085: A Real World Observational Assessment of the Impact of Immunotherapy on the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Belqis El Ferjani, Sheenu Chandwani, Meita Hirschmann, Seydeh Dibaj, Emily Roarty, Jianjun Zhang, Waree Rinsurnogkawong, Jeff Lewis, Jack Lee, Jack A. Roth, Stephen Swisher, John V. Heymach, Thomas Burke, and George R. Simon
stage IV diagnosis, 87.2% with nonsquamous histology, 36.1% with bone metastasis, 29.4% with brain metastasis, 43.2% with 0–1 performance status, and 21.6% with a known EGFR or ALK mutation. A total of 233 pts had been tested for PD-L1 (78
Translating Genomics in Cancer Care
Yvonne Bombard, Peter B. Bach, and Kenneth Offit
recurrence risk within 10 years among node-negative, estrogen receptor-positive patients. 8 , 9 A second example is testing for somatic mutations in the EGFR gene to predict response to tyrosine kinase inhibitors, such as gefitinib in first-line therapy or
Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC
Cary P. Gross, Craig S. Meyer, Sarika Ogale, Matthew Kent, and William B. Wong
Type Biomarker testing was evaluated during the first 3 months after the advanced cancer diagnosis. Biomarkers examined included ALK , EGFR , ROS1 , BRAF , and PD-L1. In addition to individual biomarker testing rates, we also assessed receipt of
Similar Efficacy Observed for First-Line Immunotherapy in Racial/Ethnic Minority Patients With Metastatic NSCLC
Matthew Lee, Jianyou Liu, Emily Miao, Shuai Wang, Frank Zhang, John Wei, Julie Chung, Xiaonan Xue, Balazs Halmos, H. Dean Hosgood, and Haiying Cheng
completed, age ≥18 years, receipt of at least 1 cycle of first-line immunotherapy and at least a follow-up of 2 weeks after the last dose of immunotherapy, and no known driver alterations in EGFR , ALK , or ROS1 . This study was approved by the
Discussing Colorectal Cancer
Paul F. Engstrom
Highlights of the NCCN Oncology Research Program
by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Phase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation–Positive Non–Small Cell Lung Cancer With Acquired Resistance to First- or Third
